We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Heart Risks Prompt Change to Label for Genentech’s HIV Drug Invirase
Heart Risks Prompt Change to Label for Genentech’s HIV Drug Invirase
October 29, 2010
Labeling for Genentech’s HIV drug Invirase must now warn patients that taking it with Abbott’s Norvir, another antiviral drug, could potentially result in life-threatening cardiovascular side effects.